|Incorporating MRD Testing into Standard Practice: Are We There Yet?|
Faith Davies, MD, MBBCh, MRCP, FRCPath
|Release Date: August 27, 2018|
Expiration Date: August 27, 2019
With modern therapy, many patients with multiple myeloma are achieving a complete response, but some will still experience a relapse after treatment, in part because of the presence of minimal residual disease (MRD). Molecular remission of MRD is a goal of therapy because it may potentially improve patient outcomes, but it is important to balance the need for achieving MRD negativity with the short- and long-term side effects of therapy. Several different methods are available to monitor MRD. In this activity, Dr. Faith Davies discusses the role of MRD in patients with multiple myeloma and compares current methodologies used to measure MRD. She also outlines the clinical applicability of incorporating MRD testing into routine clinical practice.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|